Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14586412 | 0.97 | HRH3 (0.46) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL27805443 | 0.95 | HRH3 (0.47) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL29926359 | 0.95 | HRH3 (0.47) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL4451768 | 0.95 | HRH3 (0.47) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL8462300 | 0.92 | HRH3 (0.48) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL7828951 | 0.89 | HRH3 (0.44) | HRH3 | |
| SCHEMBL26161632 | 0.86 | HRH3 (0.43) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL18503201 | 0.86 | HRH3 (0.38) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL18503244 | 0.86 | HRH3 (0.38) | HRH3MEN1THRBHTTKMT2A | |
| SCHEMBL25884127 | 0.86 | HRH3 (0.46) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230271982-A1 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-9850276-B2 | Bidentate-binding modulators of LRRK2 and JNK kinases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160185818-A1 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | HRH3 1667/4885MEN1 139/4885THRB 2795/4885 |
| US-20160185818-A1 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES | LRRK2, PINK1, MAP2K3 | HRH3 2153/4885MEN1 3813/4885THRB 1964/4885 |
| US-20230271982-A1 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | VIP, SI, PDCD5 | HRH3 1818/4885MEN1 882/4885THRB 4407/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | HRH3 948/4885MEN1 108/4885THRB 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.